Analysis on clinical efficacy of vinorelbine combined with capecitabine (NX) and gemcitabine combined with cisplatin(GP) for recurrent metastatic breast cancer after anthracycline- and taxane- treatment

Abstract

Abstract: AIM: To observe the clinical efficacy and security of vinorelbine combined with capecitabine (NX) and gemcitabine combined with cisplatin(GP) for recurrent metastatic breast cancer after anthracycline- and taxane- treatment (ATRMBC).METHODS: 41 ATRMBC patients were divided into NX group(18 cases) and GP group(23 cases).NX group:capecitabine 2000 mg/m² orally days 1-14 and vinorelbine 25 mg/m² intravenously days 1 and 8,21 days was a cycle.GP group:cisplatin 20 mg/m² intravenously days 2 through 5 and gemcitabine intravenously 1000 mg/m² on days 1 and 8,21 days was a cycle.The dose was adjusted according to adverse effects.The efficacy was evaluated every 2 cycles.RESULTS: All patients were eval- uated for efficacy and toxicity. NX group:one of the 18 patients (5.5%) showed complete response, while 9 patients (50%) showed partial response; the objective response rate was 55.5%. Stable and progressive disease was observed in 4(22.2%) and 4 patients (22.2%), respectively.The median time to progression was 6.3 months;GP group:an objective response was achieved in 13 patients (56.5%). A complete response was achieved in 2 patients (8.9%); partial response in 11 patients (47.8%);stable disease in 5 patients (21.7%), and progressive disease was observed in 5 patients (21.7%).The median time to progression was 6.5 months.There was no significant difference between both groups(P>0.05).The common toxicities included myelosuppression,gastrointestinal reactions,hand-foot syndrome,phlebitis.The incidence rates of platelet decreased and the incidence rate of gastrointestinal reactions in GP group were higher than those in NX group, and there were differences between the two groups (P<0.05),the incidence rate of hand-foot syndrome in NX group was higer than that in GP group, and there were significant differences between the two groups(P<0.01).CONCLUSION: Vinorelbine combined with capecitabine (NX) and gemcitabine combined with cisplatin(GP) are effective for patients with ATRMBC.The hematologic and non-hematologic toxicities are well tolerated.

Key words: Metastatic breast cancer, Vinorelbine, Capecitabine, Gemcitabine

CLC Number:

R737.9

ZHU Yi-ping, SHENG Li-li, WANG Lu, JI Zhao-ning. Analysis on clinical efficacy of vinorelbine combined with capecitabine (NX) and gemcitabine combined with cisplatin(GP) for recurrent metastatic breast cancer after anthracycline- and taxane- treatment[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2013, 18(8): 918-923.

References

[1] Moulder S, Hortobaqyi GN. Advances in the treatment of breast cancer[J].Clin Pharmacol Ther,2008,83(1):26-36.
[2] Moreno-Aspitia A, Perez EA. Anthracycline- and/or taxane-resistant breast cancer: results of a literature review to determine the clinical challenges and current treatment trends[J].Clin Ther,2009,31(8):1619-1640.
[3] 徐兵河.蒽环类耐药性乳腺癌治疗策略[J].中华肿瘤杂志,2007,29(4):241-244.
[4] Langkjer ST, Ejlertsen B, Mouridsen H, et al.Vinorelbine as first-line or second-line therapy for advanced breast cancer: a Phase I-II trial by the Danish Breast Cancer Co-operative Group[J].Acta Oncol,2008,47(4):735-739.
[5] Wang J,Lohman GJ,Stubbe J,et al.Mechanism of inactivation of human ribonucleotide reductase with p53R2 by gemcitabine 5'-diphosphate[J].Biochemistry,2009,48(49):11612-11621.
[6] Shulga N,Wilson-Smith R,Pastorino JG,et al.Hexokinase II detachment from the mitochondria potentiates cisplatin induced cytotoxicity through a caspase-2 dependent mechanism[J].Cell Cycle,2009;8(20):3355-3364.
[7] Heinemann V.Role of gemcitabine in the treatment of advance and metastatic breast cancer[J].Oncology,2003,64(3):191-206.
[8] Brito LG,Andrade JM, Lins-Almeida T,et al.Safety and efficacy of gemcitabine plus cisplatin combination in pretreated metastatic breast cancer patients[J].Med Oncol,2012,29(1): 33-38.
[9] Stemmler HJ,Gioia D,Freier W, et al.Randomised phase II trial of gemcitabine plus vinorelbine vs gemcitabine plus cisplatin vs gemcitabine plus capecitabine in patients with pretreated metastatic breast cancer[J].Br J Cancer,2011,104(7):1071-1078.
[10] Ngan VK,Bellman K,Hill BT,et al.Mechanism of mitotic block and inhibition of cell proliferation by the semisynthetic Vinca alkaloids vinorelbine and its newer derivative vinflunine[J].Mol Pharmacol,2001,60(1):225-232.
[11] Chan A.A review of the use of trastuzumab (Herceptin) plus vinorelbine in metastatic breast cancer[J].Ann Oncol,2007,18(7):1152-1158.
[12] Saeki T,Takashima S.Mechanism and possible biochemical modulation of capecitabine (Xeloda), a newly generated oral fluoropyrimidine[J].Gan To Kagaku Ryoho,1999,23(4): 447-455.
[13] Finek J,Holubec L Jr,Svoboda T,et al.A phase II trial of oral vinorelbine and capecitabine in anthracycline pretreated patients with metastatic breast cancer[J]. Anticancer Res,2009,29(2): 667-670.
[14] Morabito A,Filippelli G,Palmeri S,et al.The combination of gemcitabine and vinorelbine is an active regimen as second-line therapy in patients with metastatic breast cancer pretreated with taxanes and/or anthracyclines: a phase I-II study[J].Breast Cancer Res Treat,2003,78(1):29-36.
[15] 徐兵河,李凯,刘端琪,等.吉西他滨联合顺铂治疗50例葱环类耐药性晚期乳腺癌[J].中国癌症杂志,2003,13(6):579-581.
[16] Fan Y,Xu B,Yuan P,et al.Prospective study of vinorelbine and capecitabine combination therapy in Chinese patients with metastatic breast cancer pretreated with anthracyclines and taxanes[J].Chemotherapy,2010,56(4):340-347.
[17] Milano G,Etienne-Grimaldi MC,Mari M,et al. Candidate mechanisms for capecitabine-related hand-foot syndrome[J].Br J Clin Pharmacol,2008,66(1):88-95.
[18] Saif MW.Capecitabine and hand-foot syndrome[J].Expert Opin Drug Saf,2011,10(2):159-169.
[19] Kim JH,Oh SY,Kwon HC,et al.Phase II study of gemcitabine plus cisplatin in patients with anthracycline- and taxane- pretreated metastatic breast cancer[J].Cancer Res Treat,2008,40(3): 101-105.